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Abstract: Acute lymphoblastic leukemia (ALL) accounts for almost 4000 cases annually 
in the United States, approximately two thirds of which are in children and adolescents. 
Treatment results of ALL have improved considerably in the past decade, due to an optimal 
stratification of patients and a rational use of different antileukemic agents among which 
L-asparaginase (L-ASNase) plays a fundamental role. This drug has been used in pediatric ALL 
chemotherapy protocols for almost 3 decades. In the 1970s and 1980s a chemically modified 
form of this enzyme called pegasparaginase (PEG-ASNase) was rationally synthesized to 
decrease immunogenicity of the enzyme and prolong its half-life. The different advantages of 
PEG-ASNase have been demonstrated in many clinical studies, the last of which underline the 
utility of this drug in front-line therapy of ALL. In this review, we discuss the pharmacological 
advantages and clinical potential of PEG-ASNase and its important use in first-line treatment 
of ALL.
Keywords: pegasparaginase, acute, lymphoblastic leukemia, pegylation
Introduction
Acute lymphoblastic leukemia (ALL) is a heterogeneous group of disorders that result 
from the clonal proliferation and expansion of malignant lymphoid cells in the bone 
marrow, blood and other organs.1 This is the most common type of cancer in children 
and adolescents accounting for 23% to 25% of all malignant diseases.2 Pui et al 
report that in the 1990s, the 5-year event-free survival (EFS) rates for childhood ALL 
generally ranged from 70% to 83% in developed countries with an overall cure rate of 
approximately 80%.2 Unfortunately, the experience with adult ALL has been far less 
rewarding but treatment results have improved considerably in the past decade with 
an increase of complete remission (CR) rates to 85% to 90% and overall survival (OS) 
rates to 40% to 50%.3 For all patients, specific treatment approaches differ but generally 
consist of remission-induction therapy followed by intensification (or consolidation) 
therapy and continuation treatment. Central nervous system (CNS)-directed therapy, 
given for varying lengths of time depending on the patient’s risk, is administered in 
order to prevent meningeal progression or relapse.
L-asparaginase (L-ASNase) is an important antileukemic agent used in first-line 
treatment of a variety of lymphoproliferative disorders. It has been used in treatment 
of pediatric ALL for almost 30 years.4–8 L-ASNase was identified as a potential 
antileukemic agent in 1961 when it was isolated as an antilymphoma component of 
guinea pig serum.9,10Biologics: Targets & Therapy 2009:3 360
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In 1964 the asparaginase of bacterial origin was isolated. 
Mashburn reported the purification of Escherichia coli 
L-asparaginase (EC-L-ASNase) and demonstrated its 
tumoricidal activity.11 Currently, 3 asparaginase formulations 
are available in the United States: E. coli native L-ASNase, 
erwinase and pegasparaginase (PEG-ASNase). The antitumor 
effect of this enzyme results from the depletion of asparagine 
(ASN), an amino acid essential to lymphoblast leukemic cells 
leading to an inhibition of protein synthesis with consequent 
considerable cytotoxicity.
It has been also demonstrated that application of extended 
high dose of L-ASNase may compensate reduced leukemia 
control resulting from adoption of a reduced intensity che-
motherapy schedule (Berlin-Frankfurt-Munster backbone) 
for treatment of children with standard risk ALL.12 The role 
of L-ASNase as an antileukemia drug has been a matter of 
discussion due to the high rate of allergic reactions. The major 
limitation to the use of L-ASNase is dose limiting clinical 
hypersensitivity, which occurs in 3% to 78% of patients treated 
with unmodified forms of enzyme.6–15 However, these clinical 
complications seem to have been solved by use of modified 
versions of L-ASNase: polyethylene glycol (PEG)-conjugated 
asparaginase (pegasparaginase) has significant pharmaco-
logical advantages over native EC-L-ASNase and also allows 
adequate plasma enzymatic activity and asparagine depletion,16 
and can be substituted in cases of hypersensitivity to native 
L-ASNase. Coupling of the enzyme to PEG was identified as a 
process by which the immunogenic reactions of the drug were 
diminished without altering its antineoplastic property.17,18 
PEGylation also increases drug stability and the retention time 
of the conjugates in blood, and reduces proteolysis and renal 
excretion, thereby allowing a reduced dosing frequency.19 
Thus, conjugating the native EC-L-ASNase molecule to PEG 
has provided multiple advantages such as: a definite reduc-
tion of immunogenic properties, increased nonreactivity to 
antibodies, a considerably longer half-life and a reduction of 
the number of injections for the patient. In recent years, clini-
cal trials have established the importance of PEG-ASNase in 
frontline pediatric and adult ALL therapy. In this review we 
discuss about the advantages of PEG-ASNase and its use in 
first-line treatment of ALL.
Chemistry and pharmacology  
of the drug
Chemistry of the drug and pegylation
L-ASNase has been produced in large quantities from two 
bacterial species, E. coli and Erwinia caratovora. The 
enzyme obtained from these two sources has been found 
to have lowest toxicity among various similar enzymes.20 
E. coli produces two asparaginases, type EC-1 and EC-2.21 
The purified E. coli enzyme has a molecular weight of 133 
to 141 kDa.22,23 The chemical structure of all asparaginases 
is composed of four identical subunits, A, B, C, and D with 
an active site on each subunit. The molecular weight of each 
subunit is 22 kDa.24 Subunits A and B and subunits C and D 
form extensive interactions, resulting in dimers. Each dimer 
has two active sites which contain an aspartate residue, but 
only the tetrameric form has enzymatic activity.25,26 The 
specific activity of purified enzyme is between 300 and 
400 mmol of substrate per minute per milligram of protein.
The process known as pegylation, which consists of 
conjugating biomolecules with PEG, is a well-established 
technology for increasing the circulating half-life of protein 
and liposomal pharmaceuticals. In general the advantages 
of PEGylation technology are increased bioavailability, 
increased blood circulation of the drug, optimized 
pharmacokinetics (see below), decreased immunogenicity and 
decreased frequency of administration.19 PEGs are non-toxic, 
water-soluble polymers that create a shield around the 
pegylated drug, preserving it from renal clearance, enzymatic 
degradation, and recognition by cells of the immune system.27 
Pegylation of L-ASNase was developed in the 1970s and 
1980s. Abuchowski et al17 were first to successfully couple 
PEG to L-ASNase. PEG-ASNase is formed by the covalent 
conjugation of EC L-ASNase (L-asparagine amidohydro-
lase, type EC-2, EC 3.5.1.1) to monomethoxypolyethyl-
eneglycol (total PEG portion molecular weight 5 kDa).28–30 
PEG-ASNase, which is formed by 4 identical subunits with 
interactions resulting in dimmers like EC L-ASNase, has 
similar chemical properties to EC L-ASNase with optimal 
conditions for activity at pH 7.0, and reaction temperature 
of 50 °C isoelectric point at pH 5.0.30 Pegylation covers 
immunogenic epitopes, reducing hypersensitivity reac-
tions associated with EC L-ASNase and allowing free 
access of ASN to the active sites of the enzyme while 
limiting EC L-ASNase’s uptake by the reticuloendothelial 
system, protecting its antigenic determinants from immune 
detection.27,31 This also delays the elimination of the enzyme 
by means of reticuloendothelial system, prolonging the half 
life of the drug.27,29,32 In the US, PEG-ASNase is manufactured 
by Enzon from EC L-ASNase obtained from Merck and Co. 
Inc. In Europe the PEG-ASNase product is derived from the 
Kyowa Hakko native asparaginase protein.33–36 Commercially 
available preparations for therapy are known generically as 
pegaspargase; the trade name is Oncaspar® (Enzon, South 
Plainfield, NJ, USA).Biologics: Targets & Therapy 2009:3 361
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Antineoplastic action
The antineoplastic action of L-ASNase is based on the 
assumption that tumor cells, especially lymphatic cells, 
require a huge amount of ASN to maintain their rapid malig-
nant growth. L-ASNase catalyzes the hydrolysis of L-ASN 
to L-aspartic acid and ammonia.37,38
L-ASNase has a significant effect in depletion of serum 
ASN and kills tumor cells by depriving them of an essential 
factor required for protein synthesis. Both EC L-ASNase 
and PEG-ASNase hydrolyze asparagine into aspartic acid 
and ammonia and deplete circulating asparagines from 
plasma, the main exogenous sources of ASN.39–41 Leukemic 
cells lack sufficient asparagine synthetase compared with 
normal cells, so they cannot re-synthesize the asparagine 
de novo.42 Cell cycle arrest in the G1 phase has been 
documented in the murine L5178Y cell line43 and also 
in the MOLT-4 human T-lymphoblastoid line, resulting 
in apoptosis.44
Pharmacokinetics and pharmacodynamics
In vivo studies revealed that the half-lives of Erwinia and EC 
L-ASNase are similar, with 10 hours as mean half-life.45 The 
drug seems to remain confined to the vascular space after 
administration. It has been detected in the pleural fluids and 
ascites46 but not in cerebrospinal fluid (CSF).47 PEG-ASNase, 
as well as native L-ASNase, has pharmacokinetic proper-
ties that include a monophasic half-life, a one-compartment 
model and a single elimination phase.48 The peak and trough 
levels and the area under the curve of PEG-ASNase are 
proportional to the dose. The distribution volume, clearance 
and half-life of PEG-ASNase are not dose dependent.49–51 
The elimination half-life of PEG-ASNase is approximately 
5.5 to 6 days, 5 times longer than that of EC L-ASNase and 
9 times longer than that of Erwinia ASNase.
Comparative half-lives of different types of L-ASNase 
are listed in Table 1.49,50,52 PEGylation, as shown in Table 1, 
confers a markedly prolonged half-life to the drug. Table 1 
(last row) shows 5 patients who presented hypersensitivity 
reaction to EC L-ASNase with a decreased serum T½ (hours) 
of PEG-ASNase given at 2500 IU/mq. This confirms that 
the pharmacokinetics of PEG-ASNase may be adversely 
affected by the development of antibodies directed against the 
ASNase portion. Modified enzyme is cleared more rapidly in 
patients with hypersensitivity, although the T½ remains longer 
than that of the native enzyme.50 Armstrong et al studied 
the effects of the presence of anti-PEG antibodies that are 
discussed below.63 The presence of anti-PEG antibodies was 
highly associated with rapid clearance of PEG-ASNase.
On the route of administration of PEG-ASNase, the 
adult and pediatric clinical trials reported16,53,54,93,97 show 
that intravenous (iv) administration can be used, without 
higher incidence or severity of allergic or nonallergic side 
effects than reported for intramuscular (im) or subcutaneous 
administration. The iv route of administration will elimi-
nate painful injections and achieve rapid peak levels and 
asparagine depletion. Following the im administration of 
PEG-ASNase (2500 UI/m2) the serum levels of ASN fall 
by 4 days and remained depleted for around 3 weeks.48 
After iv administration PEG-ASNase deamination of ASN 
occurred by 2 hours after administration and was sustained 
for ~3 weeks (dose of 2000 UI/m2) in adult ALL patients53 
and for ~5 weeks (dose of 2500 UI/m2) in pediatric ALL 
patients.54
PEG-ASNase penetrates poorly into the CSF.16,25,48 
However, ASN depletion in the CSF has been documented 
following both EC L-ASNase and PEG-ASNase admin-
istration and may be dose-dependent.25,48,55 The CSF ASN 
level is known to rebound once L-ASNase therapy is com-
pleted.16,48
Drug resistance
For L-ASNase and PEG-ASNase, different mechanisms 
of drug resistance have been recognized. A possible 
mechanism of resistance to L-ASNase is the development 
of  antibodies  that  neutralize  the  enzyme.55,67  The 
development of antibodies against PEG-ASNase and 
EC L-ASNase can reduce their activity, leading to 
failure of asparagine depletion after readministration of 
the drug.50,53,56–58,63 PEG-ASNase has been reported to 
cause the development of anti L-ASNase antibodies in 
L-ASNase-naive patients treated with PEG-ASP, at a rate 
Table 1 Pharmacokinetic studies of patients undergoing therapy 
with L-asparaginase
L-asparaginase 
preparation
No. 
patients
T½ (h) Dose range 
(IU/mq)
Ref.
E. coli 9 34 ± 8 2500–25000 50
E. coli 7 20 ± 6 – 49
E. colia 5 Undetectable 25000 50
Erwiniab 10 16 ± 3 25000 50
Erwinia 13 6,4 ± 5 30000 52
PeG 25 357 ± 243 500–8000 49
PeG 10 138 ± 78 2500 50
PeGc 5 44 ± 6 2500 50
aPatients with previous hypersensitivity to E. coli L-asparaginase.
bintravenous administration (all others intramuscular).
cPatients with previous hypersensitivity to E. coli L-asparaginase, treated with PeG-ASNase.Biologics: Targets & Therapy 2009:3 362
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of up to 12% in children48,60 and 4% to 15% in adults.53,62 
The presence of circulating anti-PEG was very closely 
associated with rapid clearance of PEG-ASNase, which 
could consequentially render the treatment ineffective.63 
The IgG antibody produced can be associated with type II 
immune allergic reactions. Antibody development may 
also occur in patients who do not show clinical allergy 
symptoms (silent hypersensitivity).55,56 It has been 
reported that prior exposure to EC L-ASNase increases 
the development of anti-PEG-ASNase antibodies, and 
patients who had developed anti-L-ASNase antibodies to 
L-ASNase also developed anti-PEG-ASNase antibodies in 
more than 65% of cases,64 but this could be determined by 
the potential cross reactivity of the IgG antibodies. While 
the development of antibodies does seem to be correlated 
with diminished drug effect, the clinical significance of 
such antibodies is still being debated.56,58,63
An increase in ASN synthase activity (the enzyme 
responsible for the synthesis of l-asparagine in normal cells) 
has been noted in blasts of patients with ALL clinically 
resistant to the drug64 and in murine lymphoma cells.66,67 
A concomitant increase in messenger RNA as well as 
enzyme levels for ASN synthase have been described in 
several cell lines.68,69
Another possible mechanism suspected by Gallagher70 
is that the pool of L-ASNase sensitive cells may produce 
cytokines that control the expansion of resistant cells and 
when sensitive cells are killed by L-ASNase, resistant cells 
escape from regulatory control.
In 2003 Holleman et al in 200371 associated the resistance 
to different classes of drugs like L-ASNase and prednisolone 
with impaired apoptosis in childhood ALL: caspase-3 or 
PARP [poly(ADP-ribose) polymerase] inactivation seem to 
be responsible for resistance to these drugs. Moreover, loss 
of spontaneous caspase-3 activation in vivo is associated with 
relapse in adults with ALL.72
Toxicity
The toxicity profile of L-ASNase and PEG-ASNase 
falls under two main categories, those pertaining to 
immunological sensitization to a foreign protein, and the 
adverse events related to the inhibition of protein synthesis. 
L-ASNase causes little bone marrow depression and usually 
does not affect the gastrointestinal or oral mucosa or hair 
follicles.
Toxic hypersensitivity reactions include cutaneous 
rashes, serum sickness, bronchospasm, and anaphylaxis.73 
The frequency of these reactions for EC L-ASNase ranges 
from 13% to approximately 30%.74 Data on file from the 
manufacturer (Rhone-Poulenc Rorer) of PEG-ASNase 
report in 174 patients an allergic reaction rate of 10% 
in previously nonhypersensitive patients and of 32% in 
patients hypersensitive to EC L-ASNase.75 Desensitization 
protocols have been described but have not been studied 
in large numbers of patients.76 The majority of patients 
experience evidence of hepatotoxicity with an elevation 
in transaminase and bilirubin levels and abnormal alkaline 
phosphatase levels have also been reported.57,65 A decrease 
in serum albumin, fibrinogen and serum lipoprotein levels 
is also a manifestation of liver dysfunction. Pathologically, 
fatty infiltration of the liver has been noted.76 Coagulation 
abnormalities such as low levels of clotting factors have 
been consistently demonstrated as well as deficiencies of 
antithrombin III, protein C and protein S.57,77–80 Clinically 
significant hemorrhage due to L-ASNase therapy is very 
uncommon, while thrombosis of peripheral, pulmonary or 
central nervous system occurs in up to 10% of patients.81 
Congenital procoagulant abnormalities may contribute 
to the development of thrombic complications; however, 
the role of central venous catheters and steroid therapy, 
commonly used in leukemia patients, remains to be 
clarified.81–83 Pancreatitis, characterized by abdominal 
and/or back pain, anorexia, nausea and vomiting, is a 
well-documented complication of L-ASNase that occurs in 
10% to 16% of patients with a mortality rate between 1.8% 
and 4.6%.84,85 The mechanism of L-ASNase-induced acute 
pancreatitis is not completely understood. Pathologically, 
the pancreas is hemorrhagic, suggesting an involvement 
of coagulation abnormalities. Neurotoxicity, which 
can occur with symptoms such as depression, lethargy, 
fatigue, somnolence, confusion, irritability and agitation, 
is documented in up to 25% of adult patients treated with 
l-asparaginase,86 but rarely occur in children. This effect 
has been suggested to be a result of lack of L-ASN and 
l-glutamine in the brain.
A lower incidence of complications was found to be 
associated with PEG L-ASNase.13,33 PEG-ASNase is generally 
well tolerated by the majority of the patients and grade 3 
or 4 toxicity are rare. The primary toxicity of PEG-ASP is to 
that of immunologic reactions due to linked the exposure to 
the bacterial proteins. These reactions range from transient 
flushing or rush and urticaria (grade 1 and 2) to bronchospasm 
angioedema and anaphylaxis (grade 3–4).33 Aside from 
hypersensitivity, the major side effects of PEG-ASNase are 
due to inhibition of normal protein synthesis, similar to those 
of native L-ASNase.Biologics: Targets & Therapy 2009:3 363
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Clinical trials with PEG-ASNase
Because of low hypersensitivity and other pharmacological 
advantages, PEG-ASNase has been the subject of many clini-
cal application in the last 20 years. The PEGylated enzyme 
has been found to be safe for most patients allergic to EC 
L-ASNase and the delayed plasma clearance seems to have 
solved the problem of the need for frequent medication, but 
some questions need to be readdressed. In this section we 
report phase I and II clinical trials of PEG-ASNase followed 
by a discussion of first-line therapy.
Phase i trials
Ho et al conducted a phase I dose-escalation study in which 
31 adult patients received iv PEG-ASNase (dose range 
500 to 8000 IU/m2) over 1 hour fortnightly.31,49 The mean 
half-life of the drug was 357 hours, suggesting the use of a 
2-weekly treatment interval. Three patients developed ana-
phylactic reactions (one patient from a 500 dose, one from a 
2000 IU/m2, one from 4000 IU/m2) and hyperglycemia and 
hepatic dysfunction were other major associated toxicities. 
This study has been considered the base for subsequent trials, 
which adopted the same range of doses in between 2000 and 
2500 IIU/m2 for clinical studies.
In another phase I study Vieira Pinheiro et al87 infused 
500 IU/m2 of PEG-ASNase in children with relapsed ALL, 
reaching the goal to maintain serum L-ASNase activity 
(100 IU/L) adequate for requisite depletion of L-ASN. 
Most of the patients responded well to this low dose for at 
least 1 week, suggesting that with careful drug monitoring, 
lower doses may be administered successfully. Taylor et al 
in 200188 conducted a phase I clinical trial and pharmaco-
dynamic evaluation of PEG-ASNase in patients who had 
advanced stage solid tumors. They administered PEG-
ASNase at doses of 250, 500, 1000, 1500 and 2000 IU/m2 
twice weekly, and obtained in most cases a low level of 
L-ASN for 14 days. L-ASN levels were extremely low 
for 2 weeks (except in patients receiving 250 IU/m2), 
with most prolonged depletion at 2000 IU/m2. Grade 1–2 
hypersensitivity reactions were most frequently reported at 
the 2000 IU/m2 dose.
Phase ii trials
In 1995 Ettinger et al reported the results of a multicenter, 
phase II, open label clinical trial (ASP-201A) conducted 
with patients with recurrent ALL.33 Twenty-one patients 
received a single dose of pegaspargase (2000 IU/m2 every 
weeks) during an initial 14-day investigational window then 
followed by vincristine 1.5 mg/m2 weekly × 3, prednisone 
40 mg/m2/day × 21, doxorubicin 40 mg/m2 and intrathecal 
chemotherapy beginning on day 14. All had previously 
received L-ASNase . Of the 18 evaluated for response on 
day 14 after the window with PEG-ASNase monotherapy, 
3 (17%) achieved a complete response and 1 (6%) a partial 
response for a combined response rate of 23%. By completion 
of the 35-day induction period, 78% (14 of 18) of evalu-
ated patients achieved complete or partial remission. Five 
patients experienced mild urticaria and mild local allergic 
reactions. There was no evidence of anaphylactic problems 
during the treatment. The incidence of hyperglycemia and 
pancreatitis was less than expected from the studies with 
native L-ASNase.
Aguayo et al achieved a completed response rate of 
22% in 22 adults patients with recurrent ALL treated with 
PEG-ASNase, methotrexate, vincristine and prednisone. The 
chemotherapy protocol consisted PEG-ASNase 2500 IU/m2 
on days 1 and 14.89
Douer et al treated 14 adult patients with ALL subjected 
to 2000 IU/m2 on day 16 of the multi-agent protocol and 
obtained 93% complete response. The other agents included 
vincristine, prednisone and daunorubicine.90
Muss et al treated 21 patients with non-Hodgkin’s 
lymphoma with 2000 mg/m2 PEG-ASNase and the drug 
displayed modest activity in this heterogenous group 
of patients because only two partial responses were 
achieved.91
First-line treatment of ALL  
with PeG-ASNase
Here we review the experience with PEG-ASNase as a 
front-line treatment for patients with ALL. Randomized 
clinical trials in children48,92 and nonrandomized trials in 
adults,53,62,90,93 demonstrated that substitution of PEG-ASNase 
for EC L-ASNase in polychemotherapy regimens for 
ALL has similar efficacy. The Children’s Cancer Group 
(CCG) carried out a randomized comparison between 
PEG-ASNase (2500 IU/m2 × single dose on day 1) and 
native L-ASNase (6000 IU/m2 weekly × 3 doses).94 The 
overall complete response rates after 4 weeks were 
comparable: 98% for PEG-ASNase vs 100% for the native 
drug, but PEG-ASNase produced a faster rate of blast 
clearance than the native drug (63% vs 47% at day 7, 96% vs 
83% at day 14). Another randomized trial by CCG48 has been 
conducted comparing EC L-ASNase and PEG-ASNase in 
treatment of 118 children with newly diagnosed standard-risk 
ALL. PEG-ASNase was administered at a dose of 2500 IU/m2, 
im on day 3 of the 4-week induction phase and on day 3 of Biologics: Targets & Therapy 2009:3 364
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each of two 8-week delayed intensification phases. Native 
L-ASNase was administered at a dose of 6000 IU/m2 im 
3 times weekly for 9 doses during induction and for 6 doses 
during each delayed intensification phase. In patients who 
received PEG-ASNase, the number of days of asparaginase 
activity exceeded 0.03 IU/mL and was greater than the 
number of days in native enzyme-treated subjects during both 
the induction and delayed intensification phases of treatment. 
With a median follow-up of 3.2 years, the 3-year EFS rates 
were approximately 80% in both arms, but even if adverse 
events, infections, and hospitalization were similar between 
arms, the native arm presented a antibodies high-titer associ-
ated with low asparaginase activity. As a result of this study,48 
which demonstrated similar sustained depletion of serum ASN 
concentrations in patients receiving PEG-ASNase compared to 
those receiving EC L-ASNase, on July 24, 2006, the US Food 
and Drug Administration granted approval for PEG-ASNase 
for the first-line treatment of children with acute ALL as a 
component of a multiagent chemotherapy regimen.60
In addition to these pediatric studies on safety, toler-
ability and efficacy of PEG-ASNase in first-line treatment 
of ALL, studies focusing the administration schedule have 
been reported.
Silverman et al compared the use of EC L-ASNase 25,000 
IU/m2 weekly 3 × 30 doses and PEG-ASNase 2500 IU/m2 
every 2 weeks × 15 doses during intensification therapy. 
EFS at 5 years was 80%, 84% ± 4% for native L-ASNase 
and 78% ± 4% for PEG-ASNase-treated patients (p = 0.29).92 
The 5-year EFS for patients treated with less than 25 weeks 
of any L-ASNase vs at least 26 weeks of L-ASNase were 
73% ± 7% and 90% ± 2%, respectively (p = 0.01).
The problem of the weekly or biweekly administration 
of PEG-ASNase has been studied also by Abshire who 
carried out a randomized phase II95 comparing weekly 
with biweekly PEG-ASNase administration (2500 IU/m2) 
during ALL reinduction. In the chemotherapy schedule 
were also included vincristine (1.5 mg/m2 weekly × 4 
doses), doxorubicin (60 mg/m2 on first day), prednisone 
(40 mg/m2 daily × 29 days) and intrathecal medication 
(biweekly × 3 doses from day 1). There was a highly signifi-
cant difference (p = 0.003) in second remission rates, with 
97% (69 of 71) achieving complete response in the weekly 
group and 82% (60 of 73) in the every 2 weeks group.
Other pharmacokinetic and pharmacodynamic studies on 
PEG-ASNase were carried out in the pediatric population.16,96 
The Italian group investigated the pharmacological effects of the 
administration of PEG-ASNase given as a first-line product in 
children with ALL.16 They investigated ASP serum enzymatic 
activity and serum and CSF levels of ASN in 20 children 
with newly diagnosed ALL treated with PEG-ASNase as a 
first line. The drug was administered during induction at the 
dosage of 1000 IU/m2 iv on days 12 and 27 and during rein-
duction only once at the same dosage. Among the 20 patients 
treated in induction serum PEG-ASNase activity was 100 
IU/L in 18/18, 11/11 and 15/18 of the samples available on 
days 22, 25 and 27, respectively, and in 16/16, 12/15 and 5/8 
samples available on days 36, 39 and 45, respectively. In the 
15 patients treated during reinduction, serum PEG-ASNase 
activity 100 IU/L was observed in 14/15, 11/14, 6/10, and 
0/12 samples available on days 11, 15, 18 and 23, respectively, 
after the administration of the drug. CSF asparagine levels were 
below the detection limit of the method only in a few patients 
during both induction and reinduction. They concluded that 
PEG-ASNase given as a first-line L-ASNase product allowed 
adequate plasma enzymatic activity and asparagine depletion 
during both exposures to the drug even if CSF asparagine 
depletion was inadequate.
These experiences with pediatric patients demonstrate 
that PEG-ASNase is safe and tolerable, with lower or 
similar frequency than other ASNase formulations of toxic 
reaction to EC L-ASNase for front-line treatment of children 
affected by ALL; it also has a more convenient administra-
tion schedule because of its prolonged half-life. There is no 
doubt that PEG-ASNase has improved treatment options 
for pediatric patients affected by ALL, but many questions 
remains especially regarding adult patients. As noted, the 
efficacy and toxicities of PEG-ASNase and EC L-ASNase 
in adult ALL have been compared only in nonrandomized 
trials.53,62,90,93 An important trial on feasibility, tolerability 
and efficacy of IV PEG-ASNase in adult ALL was carried 
out by Douer et al53 They studied pharmacodynamics and 
safety of IV PEG-ASNase during remission induction in 25 
adult ALL administrating a single dose of 2000 IU/m2 as 
part of a standard frontline induction regimen. PEG-ASNase 
administered iv was well tolerated with no allergic reaction or 
pancreatitis and a long duration of ASN depletion. The largest 
nonrandomized clinical trial to date investigating the benefi-
cial effect of PEG-ASNase in adult ALL was conducted by 
Wetzler et al62 The aim of the study was to explore differences 
in overall survival and disease-free survival of those patients 
who achieved ASN depletion compared with those who 
did not. They concluded that effective ASN depletion with 
PEG-ASNase as part of an intensive multiagent therapeutic 
regimen in ALL is feasible in adults and is associated with 
improved outcomes. These two studies confirm the feasibility 
and the efficacy of PEG-ASNase in first-line therapy also Biologics: Targets & Therapy 2009:3 365
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for adult ALL, but some questions remain. As concluded by 
Douer, the role of dose intensification especially in patients 
with anti L-ASNase antibodies, and prolonged duration of 
PEG-ASNase administration, need further study. Similarly, 
further studies are needed also to clarify the effects of inten-
sifying the dose of PEG-ASNase to achieve prolonged CSF 
asparagines depletion.
A question that remains to be addressed is how anti 
L-ASNase and PEG antibodies formation affects ALL 
patient outcome. The effect of neutralizing antibodies on 
ALL outcome is controversial. The experience of Woo 
et al suggests there is no effect on the outcome of overall 
treatment in patients with hypersensitivity to the drug,98 
but Panosyan et al showed that patients with neutralizing 
antibodies without signs of clinical allergy had a signifi-
cantly worse outcome than patients who did not develop 
antibodies.56 Fu et al suggest that alternating the various 
asparaginase formulations (PEG-ASNase, high dose EC 
L-ASNase and Erwinia ASNase) during the various phases 
of ALL therapy may help circumvent the production of 
neutralizing anti-L-ASNase antibodies.32 The problem of 
developing anti-PEG antibodies has to be considered as a 
potential risk of using a PEG-conjugated drug as a front-
line treatment. As said before, Armstrong et al studied 
how antibodies against PEG adversely affect PEG-ASNase 
therapy in ALL patients.63 They tried to determine 
whether anti-PEG was associated with rapid clearance of 
PEG-ASNase in pediatric patients enrolled in the ALL 
Berlin-Frankfurt-Muenster 2000 studies. They concluded 
that the presence of anti-PEG was very closely associated 
with rapid clearance of PEG-ASNase, which explains similar 
observations with other PEG-conjugated drugs.99 For this 
reason they recommend that patients should be screened 
for pre-existing anti-PEG and routinely monitored for the 
development of anti-PEG in order to find patients for whom 
a modified dosing strategy or use of a nonPEGylated drug 
would be appropriate. The role of hypersensitivity and 
antibody development in the efficacy of PEG-ASNase in 
ALL treatment needs to be further explored in prospective 
clinical trials.
Conclusions
Many studies have demonstrated that the conjugation of 
L-ASNase with PEG has achieved the purpose of providing 
a long-duration form of the drug with a low grade of hyper-
sensitivity. The advent of PEG-ASNase partially overcame 
the large limitation of immunogenic complications associ-
ated with native versions of the drug. This agent is very 
effective and for most patients needs to be administered only 
once every 2 weeks, as opposed to the 2 or 3 times a week 
for EC L-ASNase. Clearly, administering only 1 or 2 doses 
of a drug rather than 6 to 9 with the same anti-leukemic 
efficacy is considerably more convenient. Moreover the safe 
administration to patients with hypersensitivity to the E. coli 
drug makes it valuable for reinduction therapy in selected 
patients with ALL. The optimal usage of PEG-ASNase for 
the first-line treatment of patients affected by ALL remains to 
be determined precisely, especially considering the problem 
of dose intensification, drug resistance and development of 
anti PEG-ASNase antibodies. The monetary cost to patients 
of PEG-ASNase is greater than that of native versions, 
but the reduced complications of therapy make overall 
treatment cost considerably less than that of conventional 
preparations.100,101
In the near future it is hoped that the details for an indi-
vidualized approach to therapy will be developed in order to 
exploit the maximum potential of this new important drug.
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